Real-life Use of BENART TM in Patients With Symptomatic Knee Osteoarthritis

TRB Chemedica AG50 enrolled

Overview

PMCF study to assess the effectiveness and safety of BENART in the treatment of symptomatic knee OA in a real-life clinical setting when used according to the instructions for use.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Knee Osteoarthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male or female aged between 18 and 99 years * diagnosis of symptomatic knee OA: Kellgren \& Lawrence grade II/III * physician's recommendation to use BENART TM prior to recruitment * signed informed consent Exclusion Criteria: * known allergy or hypersensitivity to any of the BENART TM components * infection or skin disease at or around the injection site * severe Inflammation, synovitis, or arthritis of the knee joint and/or any other signs of inflammation (e.g. pain causing nocturnal awakenings, knee heat,...) * history of autoimmune and crystal diseases (e.g. gout, pseudogout, hereditary hemochromatosis, ...) * evidence of lymphatic or venous stasis or serious blood disorders * known pregnancy or breast feeding * significant joint effusion (confirmed by objective clinical signs and/or ultrasound and/or puncture) * individuals who are unable to fully understand all aspects of the study that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response (including persons needing legally designated representatives, illiterate persons or persons with insufficient knowledge of local language)

Locations (1)

Praxiszentrum Elisengalerie

Aachen, Germany

Outcomes

Primary Outcomes

Change of subjective therapy evaluation (KOOS questionnaire) compared to baseline

Knee injury and Osteoarthritis Outcome Score (KOOS) to assess pain, other symptoms, activities of daily living (ADL), function in sport and recreation (Sport/Rec) and knee-related Quality of Life (QoL) on a 5-point Likert scale

Time frame: week 1, week 12, week 24, week 36

Change of pain intensity compared to baseline (visual analogue scale, VAS)

Evaluation of pain intensity by the patient on a 10 cm VAS-slider. 10 cm equals the worst pain.

Time frame: week 1, week 12, week 24, week 36

Change of patient's global assessment (overall impression of clinical OA severity on a numerical rating scale from 0 to 10)

The change of overall subjective symptom severity evaluation on a scale from 0 (very good condition) to 10 (very poor condition).

Time frame: week 1, week 12, week 24, week 36

Change of clinical global impression (overall impression of clinical OA severity of the investigator on a numerical rating scale from 0 to 10)

The change of clinical global Impression on a scale from 0 (very good condition) to 10 (very poor condition).

Time frame: week 1, week 12, week 24, week 36

Responder rate according to OMERACT-OARSI criteria

Time frame: week 24

Incidence of treatment-emergent Adverse Events

Time frame: Up to week 36

Satisfaction scale (subjective satisfaction of patient and investigator with the treatment on a 5 Point likert scale)

Subjective satisfaction on a scale from 1 (very satisfied) to 5 (very unsatisfied)

Time frame: week 1, week 12, week 24, week 36

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.